Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
Chemobrain, Mild Cognitive Impairment, Dementia, and even Alzheimer’s Disease. What do they all have in common? Neuroinflammation. According to the articles linked and excerpted below, therapies for neuroinflammation are non-conventional aka not studied and approved by the FDA.
I’m not pointing this out to criticize non-conventional, non-toxic brain health therapies in any way. When I developed chemotherapy-induced Cognitive dysfunction aka chemobrain in the late 1990’s as a result of my aggressive chemotherapy, conventional oncology had nothing to offer me for any sort of therapy.
Having studied brain health over the years, I’ve come to the conclusion that conventional/trational medicine just doesn’t offer a solution to general brain health deficiencies. If you suffer from
you and I are on our own when it comes of diagnostics and therapies.
To begin managing your own brain health, consider the three articles below. Consider :
This is by no means an exhaustive or complete list of therapies to treat brain health. I’m simply trying to start the conversation or get your to think outside the conventional medicine box.
If you have any questions or comments about brain health, scroll down the page, post a question or comment and I will reply to you ASAP.
“The World Health Organization (WHO)Trusted Source estimates that more than 55 million people worldwide live with Alzheimer’s disease or some related form of dementia. As individuals age, the prevalence of this disease doubles every 5 years past the age of 65 years. In fact, age is the most significant factor in developing Alzheimer’s.
Lisa Genova, a novelist, Ph.D. in neuroscience from Harvard University, and author of Remember: The Science of Memory and the Art of Forgetting, said in a TED Talk, “If we are lucky enough to live long enough, Alzheimer’s appears to be our brains’ destiny.”
Although diagnostic information to confirm the presence of Alzheimer’s is improving, no treatments have been effective in slowing its progression.
“Despite decades of research, we still have no disease-modifying treatment and no cure,” said Genova.”
“The human and financial cost of Alzheimer’s disease is devastating. More that 55 million people are living with Alzheimer’s disease and other causes of dementia, rising to 78 million by 2030 and 139 million by 2050. In the United States alone, the Alzheimer’s Association estimated that in 2020, more than 11 million unpaid caregivers provided 15.3 billion hours of assistance (valued at $256.7 billion) to 6.2 million people with dementia. That estimate does not include the $51.2 billion in Medicaid payments for Americans ages 65 and older living with dementia…
Protect yourself from the damage of chronic inflammation.
Science has proven that chronic, low-grade inflammation can turn into a silent killer that contributes to cardiovascular disease, cancer, type 2 diabetes and other conditions. Get simple tips to fight inflammation and stay healthy — from Harvard Medical School experts…
The potential benefit of nonpharmacologic memory-boosting strategies in the mild stages
One study from a group of Boston researchers examined 32 individuals with mild memory problems, half with mild cognitive impairment and half with mild Alzheimer’s disease dementia. They found that both groups improved their memory by simply thinking about the following question when learning new information: “What is one unique characteristic of this item or personal experience that differentiates it from others?”
Another study by Boston researchers found that 19 individuals with mild cognitive impairment could improve their ability to remember items at a virtual supermarket by simply thinking systematically about whether items were already in their cupboard before putting them in their shopping cart. Larger studies are needed, however, to determine if such memory strategies are generalizable…”
There is no cure for AD. While much remains unknown about the disease, scientists increasingly suspect that neuroinflammation may play a role…
The study’s authors successfully halted memory loss in mice with AD with the noninvasive, intranasal delivery of a compound known to resolve neuroinflammation.
The study was published in the journal Communications BiologyTrusted Source…
However, researchers have also found that the mere presence of amyloid plaques and tau tangles in the brain does not automatically mean a person has an active case of AD. Recent research suggests that neuroinflammation may be Alzheimer’s elusive trigger.
“It is still unclear whether amyloid plaque formation or inflammation starts first,” the lead author of the new study, Dr. Ceren Emre of the Karolinska Institute and currently healthcare equity analyst at ABG Sundal Collier, told Medical News Today…
“Several studies have indicated that neuroinflammation is indeed associated with neurodegenerative disease pathology. However, failures of recent clinical trials of anti-inflammatory agents in neurodegenerative disorders have emphasized the need to better understand the complexity of the neuroinflammatory process in order to unravel its link with neurodegeneration…
In this study, we aimed to understand the effects of early intervention with a potent natural anti-inflammatory agent, curcumin, on p25-mediated neuroinflammation and the progression of neurodegeneration in p25Tg mice.
The results from this study showed that curcumin effectively counteracted the p25-mediated glial activation and pro-inflammatory chemokines/cytokines production in p25Tg mice. Moreover, this curcumin-mediated suppression of neuroinflammation reduced the progression of p25-induced tau/amyloid pathology and in turn ameliorated the p25-induced cognitive impairments.
It is widely acknowledged that to treat AD, one must target the early-stage of pathological changes to protect neurons from irreversible damage. In line with this, our results demonstrated that early intervention of inflammation could reduce the progression of AD-like pathological outcomes. Moreover, our data provide a rationale for the potential use of curcuminoids in the treatment of inflammation associated neurodegenerative diseases..”